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Abstract 
 
Objectives. Our aim was to conduct a national audit assessing the impact and experience of early 
management of inflammatory arthritis by English and Welsh rheumatology units. The audit 
enables rheumatology services to measure for the first time their performance, patient outcomes 
and experience, benchmarked to regional and national comparators.  
Methods. All individuals >16 years of age presenting to English and Welsh rheumatology services 
with suspected new-onset inflammatory arthritis were included in the audit. Clinician- and 
patient-derived outcome and patient-reported experience measures were collected.  
Results. Data are presented for the 6354 patients recruited from 1 February 2014 to 31 January 
2015. Ninety-seven per cent of English and Welsh trusts participated. At the first specialist 
assessment, the 28-joint DAS (DAS28) was calculated for 2659 (91%) RA patients [mean DAS28 
was 5.0 and mean Rheumatoid Arthritis Impact of Disease (RAID) score was 5.6]. After 3 months 
of specialist care, the mean DAS28 was 3.5 and slightly >60% achieved a meaningful DAS28 
reduction. The average RAID score and reduction in RAID score were 3.6 and 2.4, respectively. Of 
the working patients ages 16–65 years providing data, 7, 5, 16 and 37% reported that they were 
unable to work, needed frequent time off work, occasionally and rarely needed time off work due 
to their arthritis, respectively; only 42% reported being asked about their work. Seventy-eight per 
cent of RA patients providing data agreed with the statement ‘Overall in the last 3 months I have 
had a good experience of care for my arthritis’; <2% disagreed.  
Conclusion. This audit demonstrates that most RA patients have severe disease at the time of 
presentation to rheumatology services and that a significant number continue to have high 
disease activity after 3 months of specialist care. There is a clear need for the National Health 
Service to develop better systems for capturing, coding and integrating information from 
outpatient clinics, including measures of patient experience and outcome and measures of ability 
to work.  
 
  
Introduction 
In 2009, the UK National Audit Office reported the cost-effectiveness of early aggressive 
treatment of RA but also significant geographical variation in RA care across the UK [1]. The UK 
National Institute for Health and Care Excellence 2009 clinical guidance (CG79) [2] and 2013 
quality standards (QS33) [3] for the treatment of RA have emphasized the importance of the early 
diagnosis and treatment of RA.  
In February 2014, the British Society for Rheumatology, with its information technology (IT) 
partner Northgate Public Services, launched a Healthcare Quality Improvement Partnership 
(HQIP)–funded national clinical audit of the management of early inflammatory arthritis (EIA).  
The audit aims to assess the early management of patients referred to English and Welsh 
rheumatology units with suspected inflammatory arthritis and to enable patients to provide 
feedback on the services provided to them and on the impact of their arthritis on their daily lives. 
The ability to work has been demonstrated to be highly important to individual’s health and 
welfare and to the wider economy, so this was also assessed within the audit [4]. The audit 
enables rheumatology services to measure for the first time their performance and patient 
outcomes and experiences benchmarked to regional and national comparators.  
Methods 
The data collection tools were developed by the audit project working group and approved for 
use by HQIP and the National Health Service (NHS) Review of Central Returns, now called the 
Burden Advice and Assessment Service. There was a pilot of the questionnaires and web-based IT 
tool prior to the audit launch in February 2014. Patient consent, using HQIP- and Review of 
Central Returns–approved processes, was obtained at baseline and recorded for all analysed 
data. Ethical approval was not required, as this was an audit.  
All individuals >16 years of age presenting to specialist rheumatology services in England and 
Wales with new-onset peripheral joint polyarthritis were included in the audit. Patients were 
included if they had RA, PsA, peripheral arthritis linked with SpA (not pure axial SpA) and 
undifferentiated arthritis, but were excluded if they had crystal arthritis or arthritis caused by 
infection (viral or septic arthritis) or linked with connective tissue disorders/vasculitis.  
Clinician-derived 28-joint DAS (DAS28) scores [5] were recorded when assessed at 
appointments, at baseline and during up to 3 months of specialist review for patients with an RA 
pattern of disease [defined by the presence of polyarticular disease (more than five joints 
involved) or pauci-articular disease with positive CCP antibodies]. Follow-up data capture was for 
RA patients only, given the quality standards being assessed are for RA.  
Patient-reported outcome and experience measures (PROMs and PREMs) and information on 
ability to work were also collected. The PROM used was the Rheumatoid Arthritis Impact of 
Disease (RAID) score [6], a validated tool for RA patients. The RAID score is a patient-derived 
composite measure of the impact of RA, assessing pain, functional capacity, fatigue, physical and 
emotional well-being, quality of sleep and coping. The overall score ranges from 0 (best) to 10 
(worst). PROM data were collected for all patients at presentation and after 3 months of specialist 
review for RA patients. Prior to this audit’s launch there were no established tools for assessing 
work status in patients with inflammatory arthritis. Following consultation with experts in the 
field and with patient representatives, a short questionnaire was developed, agreed upon and 
piloted and was completed as part of the patient follow-up questionnaire. Impact on a patient’s 
ability to work is presented for patients of working age, that is, 16–65 years.  
The PREM used was an adaptation for use at 3 months of the tool developed by the 
Commissioning for Quality in Rheumatoid Arthritis group with the UK National Rheumatoid 
Arthritis Society for patients with RA [7]. To ensure confidential feedback, PREM data were 
collected after 3 months of specialist review via individuals not involved in the patient’s care. The 
processes adopted were necessarily individual-to-individual trusts and, in general, were provided 
by non-clinical audit staff. The PREM statement analysed for this report was ‘Overall in the past 3 
months I have had a good experience of care for my arthritis’, with responses categorised as 
agree (agree or strongly agree), neither agree nor disagree, disagree (disagree or strongly 
disagree) and not answered. Individual trusts have access to the full questionnaire responses. 
Translators required for any consultations were available to assist patients with their 
questionnaires.  
Achievement of the seven National Institute for Health and Care Excellence quality standards [3] 
and information on key factors potentially impacting on patient experience and outcomes 
(catchment population, numbers of whole time equivalent consultants and specialist staff, 
availability of EIA clinics) were also assessed and are reported separately [8].  
The Medical Research Council Lifecourse Epidemiology Unit in Southampton analysed the data. 
Further details on the methodology are provided as supplementary data, available at 
Rheumatology Online. 
 
Results 
Data are presented for patients recruited from 1 February 2014 to 31 January 2015. One hundred 
and forty-three of 148 eligible NHS rheumatology providers in England and Wales registered to 
participate in the audit and 94% of these supplied data. Data from 6354 patients were analysed, 
representing >40% of expected incident RA cases.  
Details of the patient demographics, diagnoses and departmental staffing levels per head of 
population are presented elsewhere [8]. Patients were predominantly women (66%) and 70% were 
of working age (16–65 years). The majority of patients recruited were of white British origin 
(79%), but there was significant geographical variation in ethnicity. Forty-six per cent (55% of 
patients with a confirmed diagnosis) had RA diagnosed at baseline.  
DAS 28 data 
Nationally, at the point of first specialist assessment, the DAS28 score was calculated for the vast 
majority of RA patients [2659 (91%)]; when assessed within NHS regions and within Wales, the 
DAS28 was available for 99% of RA patients in Wales but for only 85% in the South of England. 
The mean DAS28, the proportion of RA patients with high (>5.1), intermediate (3.2–5.1) and low 
(<3.2) DAS28 scores and those with missing DAS28 scores at baseline nationally and by NHS 
region are shown in table 1. The mean baseline DAS28 was 5.0, with little regional variation (4.9 
in the Midlands and East of England, 5.1 in the South of England and Wales). Approximately half 
(45%) of patients had severe disease at presentation; Wales and the Midlands and East of England 
reported the highest (51%) and lowest (43%) proportion of patients with severe disease activity, 
respectively.  
Table 2 shows these data derived after 3 months of specialist care along with the proportion of 
RA patients in remission (DAS28 <2.6) and achieving a meaningful reduction in DAS28 [9]. 
Nationally the proportion of missing data at follow-up increased to 28% (23% in London and the 
North of England and 39% in Wales). The mean DAS28 for RA patients had decreased to 3.5 for all 
regions. Twenty-four per cent of RA patients at follow-up were in remission (26% in Wales, 22% 
in the South of England and Midlands and East of England regions), but 11% still had high disease 
activity (14% in London, 8% in Wales). Nationally slightly >60% of RA patients with available 
baseline and follow-up DAS28 scores achieved a meaningful reduction in DAS28 of >1.2; the 
highest and lowest achievement rates were observed in Wales and the North of England (67%) and 
the Midlands and East of England (57%), respectively. 
RAID data 
Table 3 summarizes the national and NHS regional data for RAID scores supplied by all EIA 
patients at baseline and for those with RA at follow-up. RAID scores indicated generally severe 
disease activity at the time of diagnosis of an EIA within rheumatology units; the mean score was 
5.6 nationally, with a range of 5.5 (South of England) to 5.8 (Wales and the North of England).  
RAID data at follow-up were available for 25% of patients with a confirmed RA pattern of disease. 
The national average RAID score at follow-up was 3.6, with a wider range of scores (mean 3.1 in 
the North of England to 4.2 in Wales) at follow-up than at baseline. The average reduction in 
RAID score nationally was 2.4, with the North of England achieving the highest (3.9) and Wales 
achieving the lowest (1.7) reductions in scores. At 3 months, these mean reductions fall short of 
the validated minimum clinically important difference for the RAID (defined as a reduction of ⩾3 
points or a percentage reduction of 50% from the baseline score) [10].  
 
Work data  
Tables 4 and 5 summarize the data received from patients on their ability to work and on 
whether they recalled being asked about their work. Again, very few patients (748) provided data 
and there was variation in data across the NHS regions. Twenty-six per cent of the patients 16–
65 years of age that returned their patient questionnaires reported that they were not working, 
but not because of their arthritis, or were undertaking voluntary work. Of the remaining patients 
of working age who provided data, 7% reported that they were unable to work due to their 
arthritis, 5% reported that they needed frequent time off work, 16% reported that they 
occasionally needed time of work, 37% reported that they rarely needed time off work and 42% 
reported that they had been asked about their work (49% in the South of England and in the 
Midlands and East of England; 30% in London).  
PREM data 
Table 6 summarizes the PREM data received nationally and for NHS regions. As for the RAID and 
work data, only a small number of RA patients (577) completed their questionnaires after 3 
months of follow-up; even when these questionnaires were returned, the PREM question was not 
answered by 17% of patients. Nationally 78% of RA patients providing data agreed with the 
statement ‘Overall in the last 3 months I have had a good experience of care for my arthritis’ 
(87% in London and 76% in the South of England) and <2% disagreed or strongly disagreed. The 
national and NHS regional findings summarized above disguise considerable variation at the 
individual trust level.  
 
 
 
Discussion 
This HQIP-funded audit has provided the first comprehensive national benchmarking of care 
given to people with newly diagnosed inflammatory arthritis in England and Wales. The 
population of patients recruited and the number of confirmed diagnoses at first appointment 
were largely as anticipated, with the majority of patients with a confirmed diagnosis at 
recruitment having RA.  
As reported in the other linked paper [8], data quality was generally good. Data were collected 
from the vast majority of trusts, but some trusts were unable to recruit the anticipated number of 
patients. Missing data were a particular problem for patient-derived data and for some of the 
clinician-derived follow-up data, and this should be borne in mind when interpreting the results.  
There were missing data for DAS28 in only 9% of RA patients nationally at baseline, indicating 
that the vast majority of clinicians are now calculating a DAS28 score for patients seen with RA 
within the context of the audit. Wales reported DAS28 assessment for virtually all patients, but 
rates were much lower in the South of England (85%). The variations in DAS28 reporting may 
reflect variations in practice, but could also be a reflection of data quality, with higher levels of 
missing data in the South of England. While regular assessment of disease activity, including 
DAS28, is considered good clinical practice, it only becomes mandatory in the UK when patients 
need to be assessed for biologic therapy later in the disease course. To be eligible for biologics 
in the UK, patients are required to have at least two DAS28 scores >5.1, assessed at least 1 
month apart, despite the use of at least two conventional DMARDs for at least 6 months. 
Nationally, and for each region, the highest proportion of RA patients with DAS28 data available 
had severe or moderate disease activity at presentation (84% nationally).  
Patient-derived disease activity measures were available for most EIA patients at baseline. 
Although the RAID is a validated tool for RA, it assesses domains relevant to all inflammatory 
arthritis problems and was collected at baseline to ensure that scores were available for all 
patients that were later established with a diagnosis of RA. As with the clinician-derived 
assessment (DAS28), the RAID indicated a generally severe level of disease at the point of 
presentation to secondary care. Ideally, systems need to be implemented to help identify patients 
with EIA and allow them to be seen within specialist services before their disease has reached 
severe levels. There was no evidence for significant geographical variation in disease severity at 
the first specialist review, but clinicians and patients in Wales reported the highest DAS28 and 
RAID scores at baseline. The overall range of scores was very wide, however, indicating that, 
while the majority of patients presented with moderately severe disease, there were patients 
presenting with very mild but also with very severe disease.  
Missing data for the DAS28 score at follow-up hinders interpretation of the results. The available 
data show that nearly two-thirds of patients achieved a meaningful reduction in their DAS28 
score and one-quarter achieved remission after 3 months of specialist care. This suggests that 
treatments initiated for patients with RA are having an impact in this relatively short time frame 
of specialist care for most patients. However, these results also show that 11% of patients 
nationally still have severe disease activity after 3 months of specialist care, highlighting an area 
for further improvement in the early management of RA in our patient population.  
A second RAID score was requested from all RA patients after 3 months of specialist care, but 
baseline and follow-up data were only available for 509 patients, so again this limits 
interpretation of the results. Interestingly, although the average DAS28 score was the same 
across all NHS regions after 3 months of follow-up, there was variation in the average RAID 
score, from 3.1 to 4.2. In addition, at the population level, greater improvements in DAS28 
scores were not mirrored by similar improvements in RAID scores. For example, Wales achieved a 
meaningful reduction in the DAS28 score in the highest proportion of patients, but also the 
lowest mean reduction in the RAID score. The RAID score covers more holistic aspects of the 
impact of disease on an individual, including emotional well-being and coping, than the DAS28, 
and this may in part explain this discrepancy. Further research into factors influencing response 
to treatment as recorded by DAS28 and RAID scores could improve our understanding of this 
particular result.  
The lack of a meaningfully clinically important reduction in the RAID score for the majority of 
patients is disappointing and indicates an area for improvement in managing patient’s symptoms 
and coping strategies in the early stages of their disease. This maps to the failure of the majority 
of patients to achieve a previously set treatment target [8], and is important. An explanation for 
this may lie partly in the short follow-up duration of the audit (acknowledging that DMARD 
therapy often takes >3 months to achieve full effect) and with issues around capacity to provide 
intensive review and treatment escalation. However, a further consideration is that RA has a 
serious impact on function and performance that may persist despite apparent control of the 
inflammatory burden (reflected in good DAS control). This observation highlights the need for 
rheumatologists to use tools beyond simply the DAS28 or other objective measures of 
inflammation, such as joint US, when measuring treatment response. Indeed, measures of pain, 
fatigue and physical function are perhaps the most relevant outcomes for patients, despite being 
poorly captured in routine care.  
The impact of specific treatments (steroids, DMARDs) on DAS28 and RAID scores has not been 
assessed as part of this audit but is an important area for future research. Whether patient 
education and support for self-management influences components of the RAID score is also 
worthy of exploration.  
Early arthritis most often presents in people of working age [11]. More than 70% of people 
recruited to this national audit were <66 years of age. There is overwhelming evidence that 
established inflammatory arthritis has severe and often permanent effects on work capacity, 
although there is some evidence that work retention is improving [12]. Health and social care 
interventions designed to keep people in work are therefore a crucial part of the effective 
management of inflammatory arthritis. Our data on work-related outcomes are limited because 
so many participants did not answer the work-related questions. However, the existing data 
suggest that impact on work capability is small in the very early stages of EIA. This suggests that 
early disease may be a crucial time for work-related interventions, before work instability 
translates into long-term work incapacity. The relationship between changing work status, 
demographic factors and clinical parameters is of interest and worthy of future research.  
As emphasized by Dame Professor Carol Black, interventions around work will not happen unless 
questions about work are part of the clinical consultation [13]. Previous data suggest that 
providers of rheumatology services believe that those questions are asked [13], but evidence 
from the National Rheumatoid Arthritis Society [14] suggests that the majority of patients do not 
recall being asked about work. Data from this national audit echo the findings from the National 
Rheumatoid Arthritis Society, with only 42% of patients returning the work-related questionnaire 
recalling being asked about work. Patient recall may be contributing to these statistics, but these 
data suggest an aspect of care that can readily be improved and may act as a spur for including 
work issues in the clinical consultation. In support of this important component of patient care, 
the British Society for Rheumatology is working with Cardiff University to implement a regional 
training programme across the UK to encourage clinicians to discuss work issues during 
consultations.  
In the absence of a validated composite score for the PREM, responses to the statement ‘Overall 
in the past 3 months I have had a good experience of care for my arthritis’ have been reported. 
The low proportion of RA patients completing their PREM questionnaires after 3 months of 
follow-up again limits our ability to draw any substantial conclusions from the data supplied. The 
low data return rate is disappointing, as the PREM is an important source of information on how 
trusts are meeting the needs of their patients. The low rate of data supply may relate to 
complexities linked with data collection processes. In order to protect patient confidentiality and 
encourage honest feedback, completed paper questionnaires had to be returned to individuals 
not directly involved in the patient’s clinical care and then uploaded to the database. These 
confidential processes may have impaired data capture.  
Nearly one-fifth of RA patients failed to supply a response to the question analysed for this 
report when returning the PREM questionnaire, and the reasons for this are unclear. The PREM 
questionnaire was originally developed and tested for use after 12 months of specialist care and 
was modified for use at 3 months for this audit. It is possible that patients did not feel able to 
provide reasonably detailed feedback on their experiences after just 3 months of care. At the 
time of finalising the audit questionnaires, there were no alternative validated PREMs.  
The PREM data that are available are broadly reassuring; however, trusts are encouraged not to 
be complacent in interpreting these results. Of some reassurance is the fact that only a small 
proportion of RA patients (1% nationally) reported that they disagreed or strongly disagreed with 
the PREM question on overall quality of care. Trusts receiving such feedback are encouraged to 
examine the full detail of the PREM data to explore mechanisms for gaining further feedback 
from patients and to review aspects of service provision that may impact on the patient 
experience.  
Overall, this national audit has provided clinicians with feedback on clinician- and patient-
reported outcomes, including information on ability to work, for their patients with RA, and this 
is the first time such data has been available with national and regional benchmarking. In 
addition, some limited feedback on patient experiences with rheumatology specialist services has 
been obtained. This audit has highlighted the difficulties in obtaining data within busy clinic 
settings and, in particular, highlights the difficulties in obtaining important patient-derived 
information in such settings.  
This audit has revealed a clear need for the NHS to develop better systems for capturing, coding 
and integrating information from outpatient clinics, including measures of patient experience 
and outcome and measures of ability to work. This audit is ongoing and further research using 
the data collected should help improve our understanding of the factors that influence outcome 
for patients with an EIA and RA.  
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Table 1. RA patients with mild, moderate and severe disease activity (DAS28) at the first 
appointment. 
Region DAS <3.2 at 
presentation 
[n (%)] 
DAS 3.2 – 5.1 
at 
presentation 
[n (%)] 
DAS >5.1 at 
presentation 
[n (%)] 
Missing 
[n (%)] 
Mean 
DAS 
National 271 (9.2) 1073 (36.6) 1315 (44.8) 277 
(9.4) 
5.0 (1.4) 
London 24 (8.5) 110 (39.0) 124 (44.0) 24 (8.5) 5.0 (1.4) 
Midland & East of 
England 
81 (11.0) 295 (40.1) 316 (42.9) 44 (6.0) 4.9 (1.5) 
North of England 90 (9.7) 324 (35.0) 418 (45.1) 94 
(10.2) 
5.0 (1.5) 
South of England 60 (7.6) 261 (33.1) 353 (44.8) 114 
(14.5) 
5.1 (1.4) 
Wales 16 (7.8) 83 (40.7) 104 (51) 1 (0.5) 5.1 (1.3) 
 
Table 2. RA patients with mild, moderate and severe disease activity (DAS28) at follow up. 
Region  RA 
patients 
recruited at 
follow up, n  
 DAS 28 
score at FU 
[mean (SD)] 
Remission 
n (%) 
Low 
disease 
activity n 
(%) 
Intermediate 
disease 
activity n 
(%) 
High 
disease 
activity n 
(%) 
Missing 
data n(%) 
Reduction 
in DAS 
score by 
at least 
1.2 n (%*) 
National level 2026 3.5(1) 480(24%) 196(10%) 571(28%) 217(11%) 562(28%) 780(62%) 
London 163 3.5(1) 39(24%) 20(12%) 45(28%) 22(14%) 37(23%) 70(63%) 
Midlands and 
East of 
England 
568 3.5(2) 127(22%) 51(9%) 153(27%) 55(10%) 182(32%) 195(57%) 
North Of 
England 
636 3.5(1) 161(25%) 62(10%) 195(31%) 69(11%) 149(23%) 272(67%) 
South of 
England 
481 3.5(2) 107(22%) 52(11%) 140(29%) 57(12%) 125(26%) 171(60%) 
Wales 178 3.3(1) 46(26%) 11(6%) 38(21%) 14(8%) 69(39%) 72(67%) 
 
Table 3. Mean RA impact of disease scores at baseline and follow up. 
Region All EIA 
patients with 
RAID at 
baseline, n 
RAID score 
at baseline 
for all EIA 
patients, 
mean (SD) 
RA patients 
with RAID 
score at 
follow up, n 
RAID score 
at follow up 
for RA 
patients, 
mean (SD) 
RA patients 
with RAID 
score at 
baseline and 
follow up, n 
RAID 
reduction 
for RA 
patients, 
mean (SD) 
National 5975 5.6 (2) 552 3.6 (3) 509 2.4 (3) 
London 722 5.6 (2) 36 3.3 (3) 32 2.6 (3) 
Midlands and 
East of 
England 
1472 5.6(2) 166 3.9(3) 157 1.9 (3) 
  Table 4. Working age patients not working or needing time off work because of their arthritis. 
Region Not working 
because of 
arthritis 
[n (%)] 
Frequent 
time off  
[n (%)] 
Occasional 
time off 
[n (%)] 
Rarely needing 
time off [n (%)] 
Not 
answered  
[n (%)] 
National 54 (7.2) 37 (5.0) 116 (15.5) 273 (36.5) 70 (9.4) 
London 5 (8.2) 5 (8.2) 9 (14.8) 18 (29.5) 13 (21.3) 
Midland & East of England 19 (9.3) 8 (3.9) 30 (14.7) 89 (43.6) 14 (6.9) 
North of England 17 (6.2) 14 (5.1) 45 (16.4) 97 (35.3) 27 (9.8) 
South of England 7 (4.4) 8 (5) 26 (16.3) 55 (34.4) 14 (8.8) 
Wales 6 (12.5) 2 (4.2) 6 (12.5) 14 (29.2) 2 (4.2) 
(N=748 audit participants under the age of 66 who returned a patient follow up form; 198 patients 
were not working but this was not because of arthritis, or were working in a voluntary capacity only) 
 
Table 5. Working age patients reporting that they recalled being asked about their work by healthcare 
professionals. 
Region Yes [n (%)] No [n (%)] Not answered [n (%)] 
National 317 (42.4) 141 (18.9) 290 (38.8) 
London 18 (29.5) 11 (18) 32 (52.5) 
Midland & East of 
England 
99 (48.5) 39 (19.1) 66 (32.4) 
North of England 105 (38.2) 54 (19.6) 116 (42.2) 
South of England 78 (48.8) 22 (13.8) 60 (37.5) 
Wales 17 (35.4) 15 (31.3) 16 (33.3) 
 
 
Table 6. RA patients providing responses to the statement ‘overall in the past 3 months I have had a 
good experience of care for my arthritis’. 
Region  Agreed [n (%)] Neither agree 
nor disagree [n 
(%)] 
Disagree [n (%)] Not answered [n (%)] 
National 391 (78.2) 17 (3.4) 7 (1.4) 85 (17.0) 
London 27 (87.1) 0(0) 1 (3.2) 3 (9.7) 
North of 
England 
1927 5.8(2)  161 3.1(3) 146 3.9(3) 
South of 
England 
1497 5.5(2) 122 3.4(3) 109 2.7(3) 
Wales 357 5.8(2) 67 4.2(2) 65 1.7(2) 
Midland & East of 
England 
125 (79.1) 5 (3.2) 3 (1.9) 25 (15.8) 
North of England 105 (79.6) 5 (3.8) 0 (0) 22 (16.7) 
South of England 86 (75.4) 6 (5.3) 2 (1.8) 20 (17.5) 
Wales 48 (73.9) 1 (1.5) 1 (1.5) 15 (23.1) 
 
 
